BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23887585)

  • 1. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry.
    Nekulova M; Holcakova J; Nenutil R; Stratmann R; Bouchalova P; Müller P; Mouková L; Coates PJ; Vojtesek B
    Virchows Arch; 2013 Sep; 463(3):415-25. PubMed ID: 23887585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
    Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
    J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
    Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
    J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
    Coates PJ; Nenutil R; Holcakova J; Nekulova M; Podhorec J; Svoboda M; Vojtesek B
    Virchows Arch; 2018 Mar; 472(3):351-359. PubMed ID: 29484502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies raised against Xenopus p53 interact with human p73.
    Le Bras M; Delattre V; Bensaad K; Blandino G; Soussi T
    Oncogene; 2002 Feb; 21(8):1304-8. PubMed ID: 11850851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Alkhayyat R; Abbas A; Quinn CM; Rakha EA
    Histopathology; 2024 Apr; 84(5):723-741. PubMed ID: 38012539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of p63 and p73 antibodies for cross-reactivity.
    Rosenbluth JM; Johnson K; Tang L; Triplett T; Pietenpol JA
    Cell Cycle; 2009 Nov; 8(22):3702-6. PubMed ID: 19855172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues.
    Sethi I; Romano RA; Gluck C; Smalley K; Vojtesek B; Buck MJ; Sinha S
    BMC Genomics; 2015 Aug; 16():584. PubMed ID: 26251276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck.
    Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
    Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site.
    Orzol P; Holcakova J; Nekulova M; Nenutil R; Vojtesek B; Coates PJ
    Histol Histopathol; 2015 May; 30(5):503-21. PubMed ID: 25510918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity.
    Uchida K; Ross H; Lotan T; Pignon JC; Signoretti S; Epstein JI; Illei PB
    Hum Pathol; 2015 Mar; 46(3):384-9. PubMed ID: 25548110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 family members and human cancers.
    Bénard J; Douc-Rasy S; Ahomadegbe JC
    Hum Mutat; 2003 Mar; 21(3):182-91. PubMed ID: 12619104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of ΔNp63 expression in lung non-small cell carcinomas.
    Nonaka D
    Am J Surg Pathol; 2012 Jun; 36(6):895-9. PubMed ID: 22367298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of p73 antibodies in patients with various types of cancer: immunological characterization.
    Tominaga O; Unsal K; Zalcman G; Soussi T
    Br J Cancer; 2001 Jan; 84(1):57-63. PubMed ID: 11139314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of p53, p63 and p73 protein and mRNA for DMBA-induced hamster buccal-pouch squamous-cell carcinomas.
    Chen YK; Huse SS; Lin LM
    Int J Exp Pathol; 2004 Apr; 85(2):97-104. PubMed ID: 15154915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p63 (TA and deltaN isoforms) in human primary well differentiated buccal carcinomas.
    Chen YK; Hsue SS; Lin LM
    Int J Oral Maxillofac Surg; 2004 Jul; 33(5):493-7. PubMed ID: 15183414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiles of p53, p63, and p73 in benign salivary gland tumors.
    Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A
    Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer.
    Tannapfel A; Schmelzer S; Benicke M; Klimpfinger M; Kohlhaw K; Mössner J; Engeland K; Wittekind C
    J Pathol; 2001 Sep; 195(2):163-70. PubMed ID: 11592094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
    Muttray AF; Cox RL; Reinisch CL; Baldwin SA
    Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73.
    Petitjean A; Ruptier C; Tribollet V; Hautefeuille A; Chardon F; Cavard C; Puisieux A; Hainaut P; Caron de Fromentel C
    Carcinogenesis; 2008 Feb; 29(2):273-81. PubMed ID: 18048390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.